Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from euglena Co., Ltd. ( (JP:2931) ) is now available.
Euglena Co., Ltd. has reported a significant increase in its financial performance for Q3 FY2025, driven primarily by growth in its healthcare business. The company’s sales and operating profit have seen substantial year-on-year increases, with adjusted EBITDA rising by 68% and operating profit multiplying sixteenfold. This growth is attributed to the consolidation of Saticine Medical, organic growth in direct sales, and company-wide profitability initiatives. Despite the healthcare sector’s progress exceeding expectations, the biofuel segment lagged slightly behind. The company has revised its full-year forecast upwards for adjusted EBITDA and operating profit, anticipating record levels, while maintaining its revenue forecast.
The most recent analyst rating on (JP:2931) stock is a Hold with a Yen461.00 price target. To see the full list of analyst forecasts on euglena Co., Ltd. stock, see the JP:2931 Stock Forecast page.
More about euglena Co., Ltd.
Euglena Co., Ltd. operates in the healthcare industry and is listed on the Prime Market of the Tokyo Stock Exchange. The company focuses on healthcare products and services, with significant contributions from its subsidiaries such as Euglena, Qsai, and Saticine Medical.
Average Trading Volume: 749,518
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen57.23B
See more insights into 2931 stock on TipRanks’ Stock Analysis page.